CYCuma Yesildas

Cuma Yesildas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cuma Yesildas has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Renal Safety of SGLT-2 Inhibitors in Patients Undergoing Coronary Angiography: A Focus on Glycemic Status and Contrast-Induced Nephropathy

    by Muhammed Adıyaman, Rıdvan Bora, Burak Toprak, Mustafa Demir, Cuma Yeşildaş, İsMail Türkay Özcan, Emrah Yeşil, Özcan Örsçelik

    Background: Contrast-induced nephropathy (CIN) is a common complication after coronary angiography (CAG), especially in patients with diabetes. Sodium–glucose cotransporter-2 (SGLT-2) inhibitors are well known for their cardio–renal protective effects, but their impact on CIN remains unclear. This study aimed to evaluate the renal safety of SGLT-2 inhibitors in patients undergoing CAG and to examine the role of glycemic control in the risk of CIN. Methods: This retrospective study included 270 patients with type 2 diabetes who underwent elective or urgent CAG. Patients were divided into SGLT-2 users (n = 127) or non-users (n = 143). Demographic characteristics, comorbidities, laboratory data, and antidiabetic therapies were collected. CIN was defined as a ≥25% or ≥0.5 mg/dL increase in serum creatinine within 48 hours after contrast exposure. Hemoglobin A1c (HbA1c) categories were used to perform subgroup analyses. Results: The incidence of CIN was similar between SGLT-2 inhibitor users and non-users (18.1% vs. 14.7%; p = 0.447). Patients administered SGLT-2 inhibitors had higher HbA1c but lower uric acid levels. Overall, renal function decline was more evident in patients with HbA1c >6.4%; however, SGLT-2 inhibitor users showed a milder decrease in estimated glomerular filtration rate (eGFR). The frequent use of metformin and insulin may also influence CIN outcomes. Conclusions: SGLT-2 inhibitors appear to be safe during CAG and may reduce the risk of CIN in patients with poorly controlled diabetes. Larger prospective studies are required to confirm these findings.

  • Distribution of Forensic Cases in Admitted to the Emergency Department of a University Hospital in the Year of the Pandemic Onset and One Year Before

    by Mehmet Burak Peköz, Halil Oktay Usluer, Hüseyin Şahin, Cuma Yeşildaş

    Aim: In light of the societal shifts brought about by the pandemic, alterations were noted in both the distribution and characteristics of forensic cases presenting at the emergency department. This study aimed to assess the changes in the features of forensic cases admitted to the emergency department before and during the COVID-19 pandemic. Material and Methods: An observational cross-sectional study was conducted at the Department of Emergency Medicine, Tekirdag Namik Kemal University, spanning from April 1, 2019, to March 31, 2021. The timeframe from April 1, 2019, to March 31, 2020, was designated as the "COVID-19 pre-pandemic period" (n = 1101), while the period from April 1, 2020, to March 31, 2021, was termed the "COVID-19 pandemic period" (n = 685). Patient records from the emergency department were retrospectively examined. Results: Among the 1786 forensic cases analyzed, 71.6% were male, with a mean age of 32.68 ± 15.67 years. Predominant case types included assault/battery (28.7%), road traffic accidents (25.1%), and occupational accidents (20.9%). While 61.6% of cases occurred during the pre-pandemic period, 38.4% were recorded during the pandemic. A significant increase was observed in the frequency of forensic cases among emergency department admissions during the pandemic compared to the pre-pandemic period (1.5% vs. 1.7%, p = 0.001). Moreover, during the pandemic period, there was a notable rise in the age of forensic cases, frequency of hospitalized cases, duration of hospitalization, and occurrences of occupational and motorcycle accidents, whereas incidents of assault/battery and traffic accidents decreased significantly (p < 0.05). Additionally, there was a statistically significant difference in the distribution of cases across different months during the pandemic compared to the pre-pandemic period (p < 0.001). Conclusion: Despite an overall decrease in the number of forensic cases during the pandemic, a heightened intensity of such cases was observed among hospital admissions. Notably, individuals admitted during the pandemic were older, experienced more frequent and prolonged hospitalizations, and were involved in fewer assault/battery and traffic accident cases but more occupational and motorcycle accidents.

  • Open Access

    The effect of ferric carboxymaltose treatment on the Tp-e interval and the Tp-e/QT and Tp-e/QTc ratios in heart failure patients with iron deficiency

    by Emrah Yesil, Hakan Uyar, Ozcan Orscelik, Bugra Ozkan, Mustafa Demir, Cuma Yesildas, Ismail Turkay Ozcan, Ahmet Celik

    Aim In heart failure (HF) patients with iron deficiency, cardiac electrical irregularity is a cause of arrhythmias. The aim of our study was to evaluate the effect of ferric carboxymaltose (FCM) treatment on T wave peak to end (Tp-e) interval and the Tp-e / QT and Tp-e / corrected QT (QTc) ratios that reflect the transmural dispersion of repolarization in HF patients with iron deficiency. Material and methods   Forty HF patients with iron deficiency that were treated with FCM were included in our single center, observational study. Repolarization parameters on electrocardiograms recorded before and 12 wks after FCM treatment were compared. Additionally, these parameters were compared with ventricular repolarization parameters of 40 healthy age and gender matched individuals and with another group of 40 HF patients without iron deficiency. Results In the HF patients with iron deficiency, the Tp-e interval and the Tp-e / QT and Tp-e / QTc ratios before FCM treatment were 103.7±19.1 ms, 0.25± 0.04, 0.23±0.04, respectively. These values were higher compared to the healthy the group and HF group without iron deficiency (pConclusion FCM treatment of HF patients with iron deficiency corrects prolonged Tp-e interval and high Tp-e / QT and Tp-e / QTc ratios, which are risk factors for ventricular arrhythmias.


  • Open Access

    Could presystolic wave be a predictor for subclinical left ventricular diastolic dysfunction in ankylosing spondylitis?

    by Çağlar Özmen, Neslihan Gökçen, Rabia Akilli, Cuma Yeşi̇lDaş, Ayhan Usal

    Purpose: The aim of this study was to evaluate the clinical significance of presystolic wave in the detection of diastolic dysfunction in ankylosing spondylitis patients. Materials and Methods: In this cross-sectional study, 59 patients and 65 healthy controls were included in the study. Ankylosing Spondylitis Disease Activity Score, Bath Ankylosing Spondylitis Metrology Index, Maastricht Ankylosing Spondylitis Enthesitis Score and Bath Ankylosing Spondylitis Functional Index was eveluated. The Doppler tissue-imaging and presystolic wave measurements were performed by same cardiologist who was blinded to study details. Results: Presystolic wave was detected in 26.6% of the whole study population; in 37.3% of patients and 16.9% of the control group. When the patient and control groups were divided into two subgroups according to the presence or absence of presystolic wave; myocardial performance index, transmitral E wave velocity, E/A ratio, left ventricular outflow tract velocity and septal e’ wave velocity were statistically significant in subjects with presence presystolic wave in both groups. In the univariate model, high c-reactive protein level, increased BASMI and BASFI scores and elevated myocardial performance index were determined as risk factors for the presence of presystolic wave in ankylosing spondylitis patients. Conclusion: The assessment of presystolic wave on echocardiography examination may provide important information about the left ventricul diastolic function, which has a prognostic impact for ankylosing spondylitis patients.


  • Prognostic performance of copeptin among patients with acute decompensated heart failure

    by Caglar Ozmen, Onur Sinan Deveci, Omer Tepe, Cuma Yesildas, İlker Ünal, İbrahim Yıldız, Rabia Eker Akıllı, Ali Deniz, Mesut Demir, Mehmet Kanadaşı, et al.

    Background In heart failure (HF), various biomarkers have been established for prognosis. However, little is known about the relevance of copeptin measurements to HF. This study aimed to explore the prognostic value of copeptin for predicting cardiovascular (CV) death or HF-related re-hospitalisation in patients with acute decompensated HF. Materials and Methods We prospectively enrolled 155 consecutive patients with acute signs and symptoms of HF. Plasma copeptin and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were measured at admission. Patients were monitored for 90 days regarding the composite endpoint of CV death or acute HF-related re-hospitalisation. Results Of the 155 patients enrolled, 40 reached the endpoint, and 115 were in a stable condition during follow-up. Patients who reached an adverse endpoint showed higher NT-proBNP and copeptin levels compared to patients in stable condition. Receiver operating characteristic curve analysis revealed that the area under curve of copeptin 0.844 (95% CI, 0.753-0.935) was superior to that of NT-proBNP 0.809 (95% CI, 0.729-0.890) for the prediction of adverse events within 90 days. Meanwhile, compared to the group with lower copeptin levels (= 34 pmol/L) were at a 10.672-times higher risk of CV death or acute HF-related re-hospitalisation. Multivariate Cox proportional hazards regression analysis revealed that increased copeptin level was a significantly independent predictor of adverse events (risk ratio, 1.051; 95% CI, 1.020-1.083;p < 0.001). Conclusion Copeptin was found to be a strong, novel marker for predicting CV death or HF-related re-hospitalisation in patients with acute decompensated HF.